ketoconazole has been researched along with Hematologic Malignancies in 4 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study evaluated the CYP3A-mediated drug-drug interaction potential of brentuximab vedotin and the excretion of MMAE." | 2.78 | CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. ( Alley, SC; Chen, R; Cooper, M; Gopal, AK; Goy, A; Grove, LE; Han, TH; Lynch, CM; Matous, JV; O'Connor, OA; Ramchandren, R, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, TH | 1 |
| Gopal, AK | 1 |
| Ramchandren, R | 1 |
| Goy, A | 1 |
| Chen, R | 1 |
| Matous, JV | 1 |
| Cooper, M | 1 |
| Grove, LE | 1 |
| Alley, SC | 1 |
| Lynch, CM | 1 |
| O'Connor, OA | 1 |
| Nawrot, U | 1 |
| Nowicka, J | 1 |
| Wlodarczyk, K | 1 |
| Minenko, SV | 1 |
| Zhukov, NV | 1 |
| Chimishkian, KL | 1 |
| Sokolova, EN | 1 |
| Ptushkin, VV | 1 |
| Paterson, PJ | 1 |
| McWhinney, PH | 1 |
| Potter, M | 1 |
| Kibbler, CC | 1 |
| Prentice, HG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations[NCT01026415] | Phase 1 | 73 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| A Phase I, First in Human, Open-label Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia[NCT03957915] | Early Phase 1 | 34 participants (Anticipated) | Interventional | 2020-05-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ketoconazole and Hematologic Malignancies
| Article | Year |
|---|---|
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brentuximab Vedotin; Cross-Over Studies; Cytochrome | 2013 |
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brentuximab Vedotin; Cross-Over Studies; Cytochrome | 2013 |
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brentuximab Vedotin; Cross-Over Studies; Cytochrome | 2013 |
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brentuximab Vedotin; Cross-Over Studies; Cytochrome | 2013 |
3 other studies available for ketoconazole and Hematologic Malignancies
| Article | Year |
|---|---|
Susceptibility to voriconazole, fluconazole, and ketoconazole of yeast isolated from patients with hematological malignancies.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Hematologic Neoplasms | 2008 |
[Prophylaxis of fungal infection in patients with hematologic neoplasms and severe neutropenia after high-dose chemotherapy].
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Antineoplastic Agents; Fluconazole; Hema | 2004 |
The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.
Topics: Amphotericin B; Antifungal Agents; Azoles; Bone Marrow Transplantation; Candida; Candidiasis; Drug R | 2001 |